Your trusted source for investing success

Tag: EMA

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report

Albireo Reports Fourth Quarter and Year-End 2017 Financial Results

Albireo Pharma (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced financial results and corporate highlights for the fourth quarter and year ended December 31, 2017.

As quoted in the press release:
“2017 was significant for Albireo, as we completed a successful Phase 2 clinical trial of

The EMA Grants Accelerated Assessment for Shire’s Lanadelumab

Shire (NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an accelerated assessment for lanadelumab (SHP643). Lanadelumab is an investigational treatment being evaluated for the prevention of angioedema attacks in patients

Tetraphase Announces Top-Line Results from IGNITE3 Phase 3 Clinical Trial of Eravacycline

Tetraphase Pharmaceuticals (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that its IGNITE3 clinical trial evaluating the efficacy and safety of once-daily intravenous (IV) eravacycline compared to ertapenem for the treatment of patients with complicated urinary tract infections (cUTI) did

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
Enter Your Log In Credentials
This setting should only be used on your home or work computer.


Privacy & Legal Policy

Privacy Policy

Investing News Network

Send this to a friend

I thought you might find this interesting:
5 Top NASDAQ Biotech Stocks: Second Sight Medical on Top